Skip to main content
FOCL
NASDAQ Industrial Applications And Services

FocalTherics Q2 Revenue Climbs 39%, but Net Loss Widens on $5.5M Warrant Charge

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$4.59
Mkt Cap
$178.039M
52W Low
$1.3
52W High
$6.4
52W Position info
253% above low
Off High info
28% below high
Rel. Volume info
4.3× avg
Market data snapshot near publication time

FOCL has more than doubled off its 52-week low of $1.3 on elevated volume (4.3× avg).

Summary

FocalTherics reported Q2 revenue of $13.2M, up 39% year-over-year, with 47% U.S. procedure growth. Net loss widened to $14.4M due to a $5.5M non-cash warrant fair-value charge. Guidance reiterated at $50-54M for 2026.


Key Events · Earnings and Guidance · FOCL

  • Q2 Revenue Up 39%

    Total revenue reached $13.2M, up from $9.5M in Q2 2025, driven by 13 Focal One system sales (vs 9) and 47% growth in U.S. procedures.

  • Net Loss Widens on Warrant Charge

    Net loss was $14.4M ($0.38/share) vs $6.4M a year ago, primarily due to a $5.5M non-cash fair-value loss on EIB warrant liability — a mark-to-market adjustment, not a cash outflow.

  • Cash Position and Guidance

    Cash and equivalents totaled $21.5M at June 30, 2026. Management reiterated 2026 revenue guidance of $50.0-$54.0M, implying 34-45% growth.

  • Discontinued Operations

    ESWL and Distribution segments are now classified as held for sale and reported as discontinued operations, leaving HIFU as the sole continuing segment.


Analysis · FOCL · Industrial Applications And Services

Final Q2 results confirm strong HIFU growth — revenue up 39% to $13.2M, gross margin improved to 55.6%, and 47% U.S. procedure growth. But the bottom line swung to a $14.4M net loss, driven by a $5.5M non-cash warrant liability fair-value adjustment tied to the European Investment Bank warrants. That charge is a mark-to-market accounting entry reflecting the higher share price, not a cash outflow or new dilution. Cash stands at $21.5M, and the company reiterated full-year guidance of $50-54M revenue. The ESWL and Distribution businesses are now classified as discontinued operations, making HIFU the sole continuing segment.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, FOCL was trading at $4.59 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $178M. The 52-week trading range was $1.30 to $6.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FOCL - Latest Insights

FOCL
Nov 05, 2026, 6:50 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.90
Real-time Price: $3.27 info
Change: -$0.630 (-16%) info
Market Cap: $162.672M info
FOCL
Nov 05, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $3.27 info
Change: -$0.980 (-23%) info
Market Cap: $162.672M info
FOCL
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $3.27 info
Change: -$0.980 (-23%) info
Market Cap: $162.672M info
FOCL
Nov 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $3.27 info
Change: -$0.980 (-23%) info
Market Cap: $162.672M info
FOCL
Aug 19, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.37
Real-time Price: $3.27 info
Change: -$1.10 (-25%) info
Market Cap: $162.672M info